StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)

Close on Nov 18, 2026Market cap $226.76MP/E –Yield –

Vanda Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Vanda Pharmaceuticals's price to sales ratio was 1.2× on Nov 11, 2026, against 1.5× a year earlier. Over the last 5 years it ranged from 1.0× to 3.3×, with a median of 1.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.2×−1.3
2025Dec 31, 20252.5×+1.0
2024Dec 31, 20241.5×+0.3
2023Dec 29, 20231.1×−0.5
2022Dec 30, 20221.6×−1.6
2021Dec 31, 20213.3×+0.3
2020Dec 31, 20203.0×−1.0
2019Dec 31, 20194.0×−3.4
2018Dec 31, 20187.4×+3.1
2017Dec 29, 20174.3×−0.7
2016Dec 30, 20165.0×+0.8
2015Dec 31, 20154.3×−6.9
2014Dec 31, 201411.1×−1.3
2013Dec 31, 201312.5×+9.3
2012Dec 31, 20123.1×−1.2
2011Dec 30, 20114.4×−51.8
2010Dec 31, 201056.2×–

More Vanda Pharmaceuticals figures

See a number that looks wrong?